About the Company
cel-sci corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. the company's lead investigational immunotherapy is multikine, which is under phase iii clinical trial for the treatment of head and neck cancer. its ligand epitope antigen presentation system (leaps), a pre-clinical patented t-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. the company also develops leaps-h1n1-dc; cel-2000 and cel-4000 are product candidates for the treatment of rheumatoid arthritis; and leaps cov-19, a product candidate to treat covid-19 coronavirus. cel-sci corporation has a collaboration agreement with the university of georgia's center for vaccines and immunology to develop leaps covid-19 immunotherapy. the company was founded in 1983 and is headquartered in vienna, virginia.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $CVM News
Why CEL-SCI Corporation (CVM) Shares Are Diving
CEL-SCI Corporation (NASDAQ:CVM) shares are trading lower by 13.9% to $2.46 Friday morning after the company priced an offering of 3.875 million shares shares of its common stock at $2.00 per ...
CEL-SCI Corporation Issues Letter to Shareholders
VIENNA, Va., March 06, 2024 -- ( BUSINESS WIRE )--CEL-SCI Corporation (NYSE American: CVM) today issued a letter to its ...
CEL-SCI Corporation
CEL-SCI Corp. is a biotechnology company, which engages in the research, development and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases.
CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results
VIENNA, Va., February 15, 2024--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended December 31, 2023, as well as key recent clinical ...
CEL-SCI Corp CVM
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
CEL-SCI Corporation Issues Letter to Shareholders
Last year we successfully moved our investigational Multikine® (Leukocyte Interleukin, Injection)* cancer therapy forward on the clinical, manufacturing, and regulatory fronts by overcoming ...
CEL-SCI Corp LSRM
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
CEL-SCI Corporation Issues Letter to Shareholders
CEL-SCI Corporation (NYSE American: CVM) today issued a letter to its shareholders. This letter will be sent to the Company’s shareholders along with the proxy to the upcoming annual meeting.
Loading the latest forecasts...